ESA therapy - The quest continues: Anemia treatment following recent national and international recommendations 2011 and 2012

Clinical Nephrology

Volumn 79, Issue 5, 2013, Pages 335-350

  Biggar, Patrick H ^a   Ketteler, Markus ^a  

^a KLINIKUM COBURG   (Germany)

Author keywords

CKD; ESA treatment; FDA; Hemoglobin targets; Iron substitution; Patients; Recommendations

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; PLACEBO;

ANEMIA; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRUG EXPOSURE; HEALTH CARE QUALITY; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; IMMUNOGENICITY; IRON DEFICIENCY; QUALITY OF LIFE; TREATMENT RESPONSE;

ANEMIA; HEMATINICS; HEMOGLOBINS; HUMANS; RED-CELL APLASIA, PURE; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 84877643067     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107695     Document Type: Article

References (151)

1. Katzung BG. Basic & clinical pharmacology, 10th edition. McGraw Hill; 2007. p. 536-538.
2. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001; 28 (Suppl 8): 19-23. doi:10.1016/ S0093-7754(01)90208-8 PubMed
3. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999; 98: 181-191. PubMed doi:10.1016/S0092-8674(00)81013-2
4. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999; 93: 2627-2636. PubMed
5. Bouzat P, Francony G, Thomas S, Valable S, Mauconduit F, Fevre MC, Barbier EL, Bernaudin M, Lahrech H, Payen JF. Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative. Crit Care Med. 2011; 39: 2099-2105. doi:10.1097/CCM.0b013e31821cb7b2 PubMed
6. Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial- macrophage interface. Curr Pharm Des. 2004; 10: 183-190. doi:10.2174/1381612043453423 PubMed
7. Rice L, Alfrey CP. Modulation of red cell mass by neocytolysis in space and on Earth. Pflugers Arch. 2000; 441 (Suppl): R91-R94. PubMed
8. Lang KS, Lang PA, Bauer C, Duranton C, Wieder T, Huber SM, Lang F. Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem. 2005; 15: 195-202. doi:10.1159/000086406 PubMed
9. Risso A, Turello M, Biffoni F, Antonutto G. Red blood cell senescence and neocytolysis in humans after high altitude acclimatization. Blood Cells Mol Dis. 2007; 38: 83-92. doi:10.1016/j. bcmd.2006.10.161 PubMed
10. Egrie J, Dwyer E, Lykos M, Hitz A, Browne JK. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood. 1997; 90: 56a.
11. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem. 2006; 281: 2024-2032. PubMed
12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316: 73-78. doi:10.1056/NEJM198701083160203 PubMed
13. Riedel E, Hampl H, Nündel M. Total correction of renal anemia in hemodialysis patients. Effects on amino acid metabolism. Proceedings of the 8th International Congress on Nutrition and Metabolism in Renal Disease. 1997; 2: 1-4.
14. Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A. Effects of optimized heart failure therapy and anemia correction with epoetin &szling; on left ventricular mass in hemodialysis patients. Am J Nephrol 2005; 25: 211-220.
15. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int. 2009; 75: 358-365. doi:10.1038/ ki.2008.467 PubMed
16. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm260670.htm (accessed September 31, 2011).
17. http://www.g-ba.de/downloads/39-261-1341/ 2011-06- 23_AM-RL-IV_Erythropoese_BAnz. pdf (accessed November 12, 2011).
18. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Notice. Kidney Int Suppl. 2012; 2: 279-335. doi:10.1038/ kisup.2012.37
19. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis. 1992; 20 (Suppl 1): 21-24. PubMed
20. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int. 1989; 36: 878-882. doi:10.1038/ki.1989.274 PubMed
21. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet. 1990; 335: 489-493. doi:10.1016/0140- 6736(90)90733-L PubMed
22. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12: 2465-2473. PubMed
23. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300: 573-578. doi:10.1136/bmj.300.6724.573 PubMed
24. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95: 888-895. doi:10.1002/ cncr.10763 PubMed
25. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S; Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997; 15: 1218-1234. PubMed
26. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamaoto DM, Schwab SC, Goodkin DA. The effects of normal vs. anemic hematocrit on hemodialysis patients with cardiac disease. N Engl J Med. 1998; 339: 584-590. PubMed doi:10.1056/NEJM199808273390903
27. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D; Canadian European Study Group. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16: 2180-2189. doi:10.1681/ ASN.2004121039 PubMed
28. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085- 2098. doi:10.1056/NEJMoa065485 PubMed
29. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. doi:10.1056/NEJMoa062276 PubMed
30. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032. doi:10.1056/ NEJMoa0907845 PubMed
31. http://renalreg.com (accessed July 13, 2012).
32. Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant. 2011; 26: 1583- 1591. doi:10.1093/ndt/gfq573 PubMed
33. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl 2): ii1-ii47. PubMed doi:10.1093/ndt/ gfh1032
34. Macdougall IC. Poor response to erythropoietin. BMJ. 1995; 310: 1424-1425. doi:10.1136/ bmj.310.6992.1424 PubMed
35. Klarenbach SW, Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology. Clinical practice guidelines for supplemental therapies and issues. Kidney Int Suppl. 2008; 110: S19-S24. doi:10.1038/ki.2008.271 PubMed
36. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1077-1083. doi:10.2215/CJN.04601007 PubMed
37. de Francisco ALM, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus. 2009; 2 (Suppl 1): i18-i26. doi:10.1093/ndtplus/sfn176 PubMed
38. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010; 77: 239-246. doi:10.1038/ki.2009.415 PubMed
39. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Zaug MF, Burger HU, Drueke TB. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol. 2009; 20: 2651-2660. doi:10.1681/ASN.2009060631 PubMed
40. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74: 791-798. doi:10.1038/ki.2008.295 PubMed
41. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363: 1146-1155. doi:10.1056/NEJMoa1005109 PubMed
42. den Elzen WPJ, Willems JM, Westendorp RG, de Craen AJ, Blauw GJ, Ferrucci L, Assendelft WJ, Gussekloo J. Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study. CMAJ. 2010; 182: 1953-1958. PubMed
43. Sinkeler SJ, Zelle DM, Homan van der Heide JJ, Gans RO, Navis G, Bakker SJ. Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients. Am J Transplant. 2012; 12: 485-491. doi:10.1111/j.1600-6143.2011.03825.x PubMed
44. Wagner M, Alam A, Zimmermann J, Rauh K, Koljaja-Batzner A, Raff U, Wanner C, Schramm L. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6: 1573-1579. doi:10.2215/CJN.00380111 PubMed
45. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B, Condorelli M. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin Cardiol. 2010; 33: 700-707. doi:10.1002/clc.20813 PubMed
46. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K. Associations between changes in hemoglobin and administered erythropoiesisstimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 1181-1191. doi:10.1681/ASN.2005090997 PubMed
47. Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol. 2010; 21: 1765-1775. doi:10.1681/ASN.2009101017 PubMed
48. Bárány P, Freyschuss U, Pettersson E, Bergström J. Treatment of anaemia in haemodialysis patients with erythropoietin: long-term effects on exercise capacity. Clin Sci (Lond). 1993; 84: 441-447. PubMed
49. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010; 5: 553-556. doi:10.2215/CJN.00490110 PubMed
50. http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4315b1-01-FDA.pdf (accessed June 3, 2011).
51. Khan FA, Shukla AN, Joshi SC. Anaemia and cancer treatment: a conceptual change. Singapore Med J. 2008; 49: 759-764. PubMed
52. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis- stimulating agents for anemia related to cancer: A metaanalysis. CMAJ 2009; 180: E62-E71. PubMed
53. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-1542. doi:10.1016/S0140- 6736(09)60502-X PubMed
54. FDA ALERT [Updated 11/8/2007]: Information for Healthcare Professionals, Erythropoiesis Stimulating Agents (ESA), [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]; http://www.fda.gov/cder/drug/InfoSheets/HCP/ RHE200711HCP.htm (accessed April 24, 2011).
55. European Medicines Agency (EMEA). Epoetins and the risk of turmour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. Public Statement, 2007; 23 October.
56. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010; 102: 301-315. doi:10.1038/sj.bjc.6605498 PubMed
57. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin (EPO) and erythropoiesis stimulating agents (ESAs) in tumor progression. Clin Cancer Res. 2011; 14; 6373-6380. PubMed
58. Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009; 14 (Suppl 1): 22-33. doi:10.1634/ theoncologist.2009-S1-22 PubMed
59. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000; 11: 530-538. PubMed
60. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984. doi:10.1681/ASN.2006091034 PubMed
61. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009; 53: 823-834. doi:10.1053/j. ajkd.2008.12.040 PubMed
62. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole- Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361: 2436-2448. doi:10.1056/NEJMoa0908355 PubMed
63. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007; 50: 1657-1665. doi:10.1016/j. jacc.2007.07.029 PubMed
64. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40: 90-103. doi:10.1053/ ajkd.2002.33917 PubMed
65. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port J Nephrol Hypert. 2009; 23: 53-63.
66. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004; 65: 2108-2112. doi:10.1111/j.1523-1755.2004.00742.x PubMed
67. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002; 13: 734-744. PubMed
68. Drüeke T, Witko-Sarsat V, Massy Z, Descamps- Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106: 2212-2217. doi:10.1161/01. CIR.0000035250.66458.67 PubMed
69. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15: 1623-1632. doi:10.1097/01. ASN.0000128009.69594.BE PubMed
70. Bailie GR, Tong L, Li Y, Mason NA, Pisoni RL, Goodkin DA, Locatelli F, Marshall MR, Inaba M, Robinson BM. Association of Intravenous Iron (ivFe) Dosing with Mortality: Findings from the DOPPS; ASN 2010, Denver, TH-FC041.
71. Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M. Transferrin saturation vs. reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int. 2003; 63: 1086-1093. doi:10.1046/j.1523-1755.2003.00826.x PubMed
72. Brissot P, de Bels F. Current approaches to hemochromatosis. Am Soc Hematol Educ Program. Hematology. 2006; 36-41. PubMed doi:10.1182/ asheducation-2006.1.36
73. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1 (Suppl 1): S9-S18. doi:10.2215/CJN.01390406 PubMed
74. Rocha LA, Barreto DV, Barreto FC, Dias CB, Moysés R, Silva MRR, Moura LA, Draibe SA, Jorgetti V, Carvalho AB, Canziani MEF. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4: 105-109. doi:10.2215/CJN.01630408 PubMed
75. Mircescu G, Gârneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006; 21: 120- 124. doi:10.1093/ndt/gfi087 PubMed
76. Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 2009; 10: 6. doi:10.1186/1471-2369-10- 6 PubMed
77. Schaefer RM, Bahner U. Iron metabolism in rhEPO-treated hemodialysis patients. Clin Nephrol. 2000; 53 (Suppl): S65-S68. PubMed
78. Macdougall IC. Proactive IV Iron Therapy in Dialysis Patients (PIVITAL); announcement during British Renal Society Conference, Manchester, England, May 1-3, 2012.
79. Parfrey P. KDIGO Reports on Upcoming Guidelines: Blood Pressure and Anemia. Presentations at ASN Philadelphia, USA, November 10, 2011.
80. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007; 370: 415-426. doi:10.1016/S0140- 6736(07)61197-0 PubMed
81. Vlaar AP, Schultz MJ, Juffermans NP. Transfusionrelated acute lung injury: a change of perspective. Neth J Med. 2009; 67: 320-326. PubMed
82. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47 (Suppl 3): S1-S146. doi:10.1053/S0272-6386(05)01814- 7
83. Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012; 27: 709-715. doi:10.1093/ndt/gfr288 PubMed
84. Bowry SK, Gatti E. Impact of hemodialysis therapy on anemia of chronic kidney disease: the potential mechanisms. Blood Purif. 2011; 32: 210-219. doi:10.1159/000329573 PubMed
85. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL. Health-related quality of life associated with rHu-EPO therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995; 25: 548-554. PubMed doi:10.1016/0272-6386(95)90122-1
86. Lopez-Gomez JM, Jofre R, Moreno F, Sanz D, Valderrabano F. Spanish cooperative renal patients quality of life in predialysis chronic renal failure patients: Effect of rHu-EPO therapy. Nephrology 1997; 3 (Suppl. 1; abstr): S309A.
87. Valderrábano F, Jofre R, López-Gómez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001; 38: 443-464. PubMed doi:10.1053/ajkd.2001.26824
88. Kusunoki M, Kimura K, Nakamura M, Isaka Y, Yoneda S, Abe H. Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease. J Cereb Blood Flow Metab. 1981; 1: 413-417. doi:10.1038/ jcbfm.1981.45 PubMed
89. Mueller C, Wodack K, Twelker K, Werner N, Custodis F, Nickenig G. Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease. Heart. 2011; 97: 1474- 1478. doi:10.1136/hrt.2010.220798 PubMed
90. Ishii Y, Sawada T, Murakami T, Sakuraoka Y, Shiraki T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a nonhuman primate model. Nephrol Dial Transplant. 2011; 26: 1157-1162. doi:10.1093/ndt/gfq601 PubMed
91. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111: 992-1000. PubMed
92. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kindney Int. 2012; 82: 235-241.
93. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJV, Singh AK, Solomon SD, Uno H, Pfeffer MA; TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011; 124: 2903-2908. doi:10.1161/ CIRCULATIONAHA.111.030411 PubMed
94. Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol. 1990; 76: 121-127. doi:10.1111/j.1365-2141.1990.tb07846.x PubMed
95. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998; 100: 79-89. doi:10.1046/j.1365-2141.1998.00521.x PubMed
96. Jelkmann W. The future of biosimilars Hospital Pharmacy Europe 2010, 48,Tuesday 26, January/ February. Available at: http://www.hospitalpharmacyeurope. com/default.asp?title = The%5Ffuture%5 Fof%5Fbiosimilars&page = article.display&article. id = 20183 (accessed August 15, 2011).
97. http://www.kvb.de/de/praxis/verordnungen/ gesetzliche-grundlagen/arzneimittel/amv-2010. html (accessed June 15, 2011)
98. http://www.kvb.de/fileadmin/data/dokumente/2_ Praxis/2.6.5_Verordnungen/Gesetzliche_ Grundlagen/ KVB-101228-SOP-AMV-Wirtschaftlichkeitsziele- 2011-Verordnung-aktuell.pdf (accessed August 15, 2011).
99. http://www.emea.europa.eu/humandocs/PDFs/ EPAR/silapo/H-760-en6pdf. (accessed August 21, 2008).
100. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, PljeSa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A; Epoetin Zeta Study Group. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010; 27: 105-117. doi:10.1007/s12325-010-0012-y PubMed
101. http://www.ema.europa.eu/humandocs/PDFs/ EPAR/eporatio/H-1033-en6.pdf EMA/522704/2009 (accessed May 24, 2010).
102. Loughnan A, Ali GR, Abeygunasekara SC. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients. Ren Fail. 2011; 33: 373-375. doi:10.3109/ 0886022X.2011.559675 PubMed
103. Schoeffski et al. Verbrauch von erythropoesestimulierenden Faktoren in der Therapie der renalen Anämie. Nieren- und Hochdruckkrankheiten, 2011; 40: 84-90.
104. Brinks V, Hawe A, Basmeleh AHH, Joachin- Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharm Res. 2011; 28: 386-393. doi:10.1007/s11095-010-0288-2 PubMed
105. EMEA. Questions and Answers on biosimilar medicines (similar biological medicinal products). 2008. Available at http://www.ema.europa.eu/do cs/en_GB/document_library/Medicine_QA/ 2009/12/WC500020062.pdf (accessed May 24, 2011).
106. Jelkmann W. The future of biosimilars Hospital Pharmacy Europe 2010, 48 January/February.
107. Rahmenvorgaben nach S 84 Abs. 7 SGB V - Arzneimittel - für das Jahr 2012 vom 30. September 2011- Deutsches Ärzteblatt. 25 November 2011 (47): A2565-A2569.
108. German text accessible at: https://www.gkv-spitz enverband.de/upload/Beschluss_011110_14362. pdf (last accessed August 7, 2011)
109. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008; 48: 1754-1762. doi:10.1111/j.1537-2995.2008.01749.x PubMed
110. Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012; 81: 727-732.
111. Bundesinstitut für Arzneimittel und Medizinprodukte. Bonn, Germany 2009; August; http:// www.bfarm.de/cln_028/nn_421158/sid_DB91 524C96D27190F0C2A9DDB5E2F4EB/DE/ Pharmakovigilanz/risikoinfo/epo.html (accessed August 15, 2011).
112. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012; 77: 8-17. PubMed
113. Seidl A, Hainzl O, Richter M, Fischer R, Boehm S, Deutel B, Haertinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity. Pharm Res 2011, November 18 (epub).
114. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012; 59: 444-451. doi:10.1053/j. ajkd.2011.11.013 PubMed
115. Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs. 2010; 11: 1030-1038. PubMed
116. Locatelli F, Fishbane S, Macdougall IC, Wiecek A, Covic C, Patel H, Cooper DS, Tang H, Chen M, Duliege AM, Mayo M, Polu KR. Safety Results from Two Phase 3 Studies of Peginesatide Treatment for Anemia in Hemodialysis (HD) Patients. Poster at ASN, 08 until 13 November 2011, Philadelphia, USA, FR-PO1571.
117. http://www.fda.gov/downloads/Advisory Committees/Committees Meeting Materials/Drugs/ O n c o l o g i c D r u g s A d v i s o r y C o m m i t t e e / UCM282292.pdf (accessed April 1, 2012).
118. http://www.medscape.com/viewarticle/742968 (accessed March 29, 2012).
119. Schatz PJ, Tong S, Mathur VS, Chen H, Leu K, Mortensen RB, Zawadzki R, Cooper DS, Stead RB, Mayo M, Polu KR, Duliege AM. Peginesatide immunogenicity in clinical studies of CKD patients. Abstract FR-PO262, ASN, San Diego, USA, 2012.
120. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008; 179: 333-337. doi:10.1503/cmaj.071131 PubMed
121. Hertig A, Ferrer-Marin F. Correction of anaemia on dialysis: did we forget physiology? Nephrol Dial Transplant. 2011; 26: 1120-1122. doi:10.1093/ndt/gfr001 PubMed
122. Mastrogiannaki M, Matak P, Mathieu JRR, Delga S, Mayeux P, Vaulont S, Peyssonnaux C. Hepatic HIF-2 down-regulates hepcidin expression in mice through epo-mediated increase in erythropoiesis. Haematologica. 2011.10.3324/ haematol.2011.056119
123. Akizawa T, Hamano T, Imai E, Matsuo S, Makino H, Watanabe T, Nitta K, Ohashi Y, Hishida A; CKD-JAC Study Group. Erythropoietin Responses in Chronic Kidney Disease: A Cross-Sectional Analysis from the CKD-JAC Study. ASN Abstract: [TH-PO243], 10.11.2011, Philadelphia, USA.
124. Anemia Management in chronic kidney disease. Rapid update February 2011 http://www.nice.org. uk/nicemedia/live/13329/52851/52851.pdf (accessed September 25, 2012).
125. http://clinicaltrials.gov/ct2/show/NCT00358215 (accessed February 22, 2012).
126. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetintreated hemodialysis patients. Kidney Int. 2003; 64: 1514-1521. doi:10.1046/j.1523-1755.2003.00229.x PubMed
127. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337- 1343. doi:10.1111/j.1523-1755.2005.00532.x PubMed
128. Brunelli SM, Lynch KE, Ankers ED, Joffe MM, Yang W, Thadhani RI, Feldman HI. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1733-1740. doi:10.2215/CJN.02390508 PubMed
129. Boudville NC, Djurdjev O, Macdougall IC, de Francisco ALM, Deray G, Besarab A, Stevens PE, Walker RG, Ureña P, Iñigo P, Minutolo R, Haviv YS, Yeates K, Agüera ML, MacRae JM, Levin A. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol. 2009; 4: 1176- 1182. doi:10.2215/CJN.04920908 PubMed
130. Keller F. Zielhämoglobin 10 g/dl - Diskussion der Gro&szling;en Studien 1998 bis 2009, Nephro-News 4 / 2010 Available at: http://www.medicom.cc/ medicom/inhalte/nephro-news/entries/NN410/ e n t r i e s _ s e c / Z i e l h a e m o g l o b i n - 1 0 - g - d l - Diskussion-der-Grossen-Studien-1998-bis-2009. php (accessed July 28, 2011).
131. Selby NM, Fonseca SA, Fluck RJ, Taal MW. Hemoglobin Variability with Epoetin Beta and Continuous Erythropoietin Receptor Activator in Patients on Peritoneal Dialysis. Perit Dial Int 2011. 10.3747/pdi.2010.00299
132. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011; 26: 3980-3986. doi:10.1093/ndt/gfr160 PubMed
133. Locatelli F, Mann JFE, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, Sulowicz W, Dougherty FC, Beyer U. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010; 73: 94-103. PubMed
134. http://clinicaltrials.gov/ct2/show/NCT00119600 (accessed August 15, 2011).
135. http://clinicaltrials.gov/ct2/show/NCT00968617 (accessed August 15, 2011).
136. http://seekingalpha.com/article/205253-merck-sditching- of-aranesp-biosimilar-highlights-followon- biologics-pitfalls May 16, 2010 (accessed August 16, 2011).
137. Besarab A, Nissenson AR, Schwartz D, Pearlman AL, Ng P, Elhalel M. Henry Ford Hospital, Detroit, MI; UCLA School of Medicine, LA, CA; Sourasky Medical Center, Tel Aviv, Israel; Medgenics, Inc., Misgav, Israel; Baylor College of Medicine, TX; Hadassah Hospital, Jerusalem, Israel. Erythropoiesis Sustained 12 Months by the EPODURE Biopump in Patients with Chronic Kidney Disease: Further Results of Phase I/II Proof of Concept Trial, ASN 2010, Denver USA, Abstract F-FC 270.
138. Besarab A, Elhalel M, Schwartz D, Shoshani E, Pearlman AL, Stern B, Ng P, Nissenson AR. Sustained Erythropoiesis (6-30 Months) by the EPODURE Biopump in Patients with Chronic Kidney Disease: Further Results of Phase I/II Proof of Concept Trial. Poster at ASN, 08 until 13 November 2011, Philadelphia, USA, FR-PO1557.
139. Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010; 12: 586-597.
140. Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A, Sung V, Terpos E. Activin receptor antagonists for cancerrelated anemia and bone disease. Expert Opin Investig Drugs. 2013; 22: 87-101.
141. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 1681-1689. doi:10.2215/CJN.05990809 PubMed
142. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammationinduced anemia. Blood. 2010; 115: 3616-3624. doi:10.1182/blood-2009-09-245977 PubMed
143. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FWK, Chapman RS, Maxwell PH, Choi P. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75: 976-981. doi:10.1038/ki.2009.21 PubMed
144. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FWK, Chapman R, Maxwell PH, Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010; 95: 505-508. doi:10.3324/haematol.2009.013136 PubMed
145. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012; 87: 392-400. doi:10.1002/ajh.23110 PubMed
146. de Francisco ALM. Individualizing anaemia therapy. NDT Plus. 2010; 3: 519-526. doi:10.1093/ ndtplus/sfq164
147. Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol. 2012; 7: 354-357. doi:10.2215/ CJN.11961111 PubMed
148. Gaweda AE, Brier ME, Aronoff GR. Validation of an Intelligent Decision Support Tool for Anemia Management. Poster at ASN, 08 until 13 November 2011, Philadelphia, USA, FR-PO1583.
149. Brier ME, Aronoff GR, Jacobs AA, Gaweda AE. Smart Anemia Manager Results in Better Hemoglobin Control and Cost Savings over a Traditional Algorithmic Approach. Poster at ASN, 08 until 13 November 2011, Philadelphia, USA, FR-PO1585.
150. Gaweda AE, Chait Y, Brier ME, GR Aronoff. Mathematical Modelling of Erythropoietin and Iron Dosing in Anemia Management. Poster at ASN, 08 until 13 November 2011, Philadelphia, USA, FR-PO1587.
151. Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011; 80: 240-244. doi:10.1038/ki.2011.141 PubMed